Work

Targeting immunosuppressive myeloid cells using nanocarriers to improve cancer immunotherapy

Year: 2015
Type: article
Abstract: In the last decade, different cancer immunotherapy approaches have been proved to produce objective clinical responses and survival benefits in cancer patients who failed conventional treatment options. However, the efficacy of cancer immunotherapy is known to be limited by tumor-induced expansion of immunosuppressive and tumor-promoting immune populations, including cells of myeloid origin (such as tumor associated macrophages –TAMs-, and myeloid-derived suppressor cells –MDSCs-). The development of increasingly powerful and widely applicable immunotherapies is therefore dependent on the availability of supporting treatments able to reduce tumor-associated immunosuppression, with good efficacy and low toxicity. Drug delivery nanosystems have been shown to improve pharmacological proprieties of anti-cancer drugs by increasing drug half-life, enhancing accumulation into tumor tissues and reducing off-target toxicity. In addition, the use of RNA delivery nanosystems is currently being explored for the development of RNA intereference (RNAi)-based anti-cancer therapeutics.The use of drug and RNA delivery nanosystems to target tumor-associated immune cells, besides tumor cells, is a far less explored approach, which is currently showing promiseas tool to improve cancer immunotherapy. In the present work we investigated two different nanotechnology-based tools to modulate the presence and function of tumor-associated myeloid cells:a modified form of gemcitabine encapsulated into lipid nanocapsules (LNC-GemC12), and ployarginine-coated nanocapsules (PolyArgNCs) loaded with short hairpin (sh) RNAs, for in vivo RNAi-based gene silencing. LNC-GemC12 and free gemcitabine hydrochloride (GemHCl, the current standard gemcitabine formulation)were found to selectively deplete both splenic and tumor-infiltrating monocytic (M-) MDSCs, following administration at a very low drug dose to EG7-OVA tumor bearing mice. Remarkably, LNC-GemC12 administration was associated with a stronger and more durable reduction of tumor-infiltrating M-MDSCs as compared withGemHCl, which resulted in the attenuation of MDSC suppressive activity towards T cells. More importantly,treatment of EG7-OVA tumor bearing mice with LNC-GemC12,prior to adoptive cell transfer therapy (ACT) with OVA-specific T lymphocytes,significantly extended mouse survival as compared to mice receiving ACT alone. Conversely, preconditioning with GemHCl at the same dose did not result in a similar survival benefit. PolyArg NCs were loaded with a fluorinated shRNA specific for mouse C/EBPβ transcription factor, which is known to be required for tumor-induced MDSC expansion and acquisition of immunosuppressive functions.PolyArgNCs loaded with the C/EBPβ-specific shRNA (NC-shC/EBPβ) efficiently down-regulated target gene expression in an immortalized MDSC cell line.In vivo, we reported a significant reduction of C/EBPβ mRNA levels in splenic and tumor-infiltrating myeloid cells, following repeated administration of NC-shC/EBPβ to mice bearing MCA203 subcutaneous sarcomas. The present datasupport the use of LNC-GemC12 as MDSC-targeted agent in cancer immunotherapy, notably in combination with ACT. As compared with standard MDSC-depleting chemotherapeutic drug formulations, LNC-GemC12 bears the potential of achieving significant effects at very low, likely not toxic, drug doses. Moreover, the use of a drug already employed in clinical oncology, combined with a biocompatible delivery nanosystem, might facilitate clinical translation.We also provided an initial evidence that shRNA-loaded PolyArg NCs allow to downregulate target gene expression in myeloid cellsin vivo, and could be exploited to therapeutically modulate tumor-associated myeloid cells.
Language: English
Subfield: Biomaterials
Open Access status: green
OpenAlex ID: W2395083282
FWCI:
Cites: 203
Cited by: 1
Related to: 10